Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible Patients with Muscle Invasive Bladder Cancer By Ogkologos - November 18, 2024 988 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Daughter Donates Hair to Mother After She Was Diagnosed with Stage... March 3, 2021 2022 ASCO Annual Meeting: Using Biomarker Testing to Avoid Radiation Therapy in... June 7, 2022 What Are Biosimilars in Cancer Treatment? September 15, 2020 2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast... July 27, 2023 Load more HOT NEWS Autumn and Letting Go Blinatumomab Increases Survival for Infants with an Aggressive Type of ALL Doctors Said Egg-Sized Tumor Was Benign. A Year Later, She’s Fighting... Woman Perfectly Breaks Down Grief Using ‘Ball In The Box’ Analogy...
